Grants4Ag – Bayer funding and testing initiatives

Grants4Ag – Bayer funding and testing initiatives

[ad_1]

Bayer have two cyclical schemes open to anyone to apply for. First introduced in 2015, the initiative has since evolved to offer researchers financial and scientific support to develop ideas for novel solutions across all research and development areas in the Division of Crop Science. Current deadline for submissions is 31st March 2023, but subsequent rounds on different themes will likely be open for applications.

“Our previous Grants4 programs succeeded in attracting top proposals in targeted niches – particularly biotech traits and biologicals,” said Phil Taylor, Open Innovation Business Partner for the Crop Science division. “The new Grants4Ag model expands the reach to a greater number of potential applicants, and therefore more diverse innovations.”

As with previous Grants4 programs, there are no formal reporting requirements and applicants retain ownership of any intellectual property developed. Taylor says the company views these grants as an initial investment with the potential to become larger-scale, longer-term collaborations with Bayer.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com

For more information and to apply, please visit the company pages.



[ad_2]
Source link

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *